Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Voss

Showing results (211-220 of 419) with videos related to

Pageof 42
Sort By:
Clinical Genitourinary Cancer|July 16, 2014
Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasisDiogo A Bastos, Ana M Molina, Vaios Hatzoglou, et al.
The British Journal of Dermatology|July 19, 2008
Loss-of-function polymorphisms in the filaggrin gene are associated with an increased susceptibility to chronic irritant contact dermatitis: a case-control studyC M de Jongh, L Khrenova, M M Verberk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 6, 2007
Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylationCourtney Nicholas, Sanjay Batra, Melissa A Vargo, et al.
British Journal of Cancer|February 25, 2016
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinomaMartin H Voss, David Chen, Mahtab Marker, et al.
Future Oncology (London, England)|October 26, 2023
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinomaToni K Choueiri, Thomas Powles, Martin H Voss, et al.
Clinical Genitourinary Cancer|May 19, 2021
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell CarcinomaSimon Chowdhury, Jeffery R Infante, Robert Hawkins, et al.
Scientific Reports|January 20, 2018
Generation and Characterization of Alloantigen-Specific Regulatory T Cells For Clinical Transplant ToleranceJames M Mathew, Jessica H Voss, Scott T McEwen, et al.
Cancer|April 23, 2013
Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and olderDarren R Feldman, Martin H Voss, Erin P Jacobsen, et al.
Scientific Reports|May 11, 2018
A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney TransplantsJames M Mathew, Jessica H-Voss, Ann LeFever, et al.
Journal for Immunotherapy of Cancer|October 5, 2018
Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancyMichael Lattanzi, Fang-Ming Deng, Luis A Chiriboga, et al.
Pageof 42

Showing results (211-220 of 419) with videos related to

Sort By:
Pageof 42
Clinical Genitourinary Cancer|July 16, 2014
Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasisDiogo A Bastos, Ana M Molina, Vaios Hatzoglou, et al.
The British Journal of Dermatology|July 19, 2008
Loss-of-function polymorphisms in the filaggrin gene are associated with an increased susceptibility to chronic irritant contact dermatitis: a case-control studyC M de Jongh, L Khrenova, M M Verberk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 6, 2007
Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylationCourtney Nicholas, Sanjay Batra, Melissa A Vargo, et al.
British Journal of Cancer|February 25, 2016
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinomaMartin H Voss, David Chen, Mahtab Marker, et al.
Future Oncology (London, England)|October 26, 2023
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinomaToni K Choueiri, Thomas Powles, Martin H Voss, et al.
Clinical Genitourinary Cancer|May 19, 2021
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell CarcinomaSimon Chowdhury, Jeffery R Infante, Robert Hawkins, et al.
Scientific Reports|January 20, 2018
Generation and Characterization of Alloantigen-Specific Regulatory T Cells For Clinical Transplant ToleranceJames M Mathew, Jessica H Voss, Scott T McEwen, et al.
Cancer|April 23, 2013
Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and olderDarren R Feldman, Martin H Voss, Erin P Jacobsen, et al.
Scientific Reports|May 11, 2018
A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney TransplantsJames M Mathew, Jessica H-Voss, Ann LeFever, et al.
Journal for Immunotherapy of Cancer|October 5, 2018
Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancyMichael Lattanzi, Fang-Ming Deng, Luis A Chiriboga, et al.
Pageof 42